Outlook Therapeutics (NASDAQ:OTLK) versus SOPHiA GENETICS (NASDAQ:SOPH) Head-To-Head Comparison

Outlook Therapeutics (NASDAQ:OTLKGet Free Report) and SOPHiA GENETICS (NASDAQ:SOPHGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Valuation and Earnings

This table compares Outlook Therapeutics and SOPHiA GENETICS’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Outlook Therapeutics N/A N/A -$58.98 million ($11.41) -0.67
SOPHiA GENETICS $62.37 million 5.06 -$78.98 million ($1.12) -4.31

Outlook Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 5.3% of Outlook Therapeutics shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Outlook Therapeutics and SOPHiA GENETICS, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Outlook Therapeutics 0 1 7 0 2.88
SOPHiA GENETICS 0 0 2 0 3.00

Outlook Therapeutics presently has a consensus target price of $46.43, suggesting a potential upside of 505.28%. SOPHiA GENETICS has a consensus target price of $8.00, suggesting a potential upside of 65.63%. Given Outlook Therapeutics’ higher probable upside, research analysts plainly believe Outlook Therapeutics is more favorable than SOPHiA GENETICS.


This table compares Outlook Therapeutics and SOPHiA GENETICS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Outlook Therapeutics N/A -3,741.39% -167.29%
SOPHiA GENETICS -113.71% -47.56% -35.80%

Volatility & Risk

Outlook Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.


SOPHiA GENETICS beats Outlook Therapeutics on 7 of the 13 factors compared between the two stocks.

About Outlook Therapeutics

(Get Free Report)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.


(Get Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.